1.
Opioids, though widely used as
analgesics, have not been seriously considered as
therapy for
rheumatoid arthritis. The present study evaluated the dose-effect and time-dependence relationships of a new peripherally selective kappa agonist,
asimadoline, in rats with
adjuvant arthritis. 2. The
arthritis was assessed by a pooled severity index combining the comprehensive criteria of oedema, radiography and histological changes, in the hind limbs.
Asimadoline was extremely effective in attenuating joint damage (by up to 80%) when administered parenterally (0.5 to 10 mg kg(-1) day(-1), i.p.) throughout the disease or during its early phase; treatment was less successful if confined to the latter stages. Ten fold higher doses were effective orally. 3. Equimolar doses of a peripherally-selective antagonist,
naloxone methiodide, and the kappa-selective antagonist, MR2266, fully reversed the peripheral anti-arthritic effects of
asimadoline (5 mg kg(-1) day(-1)), indicating that
asimadoline acts through peripheral
kappa-opioid receptors. However, an equivalent dose of MR2266 did not fully reverse the anti-arthritic effects of the highest dose of
asimadoline (40 mg kg(-1) day(-1)), suggesting a loss of kappa-selectivity at this dose. 4.
Asimadoline also exhibited
analgesic effects (mechanical nociceptive thresholds) in arthritic but not non-arthritic rats, indicating that
inflammation is necessary for
asimadoline-induced
analgesia. 5. These data confirm our previous findings that kappa-
opioids possess anti-arthritic properties and that these effects are mediated via peripheral
kappa-receptors. The present results are new in showing that the peripherally acting kappa-
opioid agonist,
asimadoline, is a potent anti-arthritic agent. Such novel drugs, essentially lacking central side effects, herald new treatments for
rheumatoid arthritis.